No Data
No Data
Imugene Ltd: Half Yearly Report and Accounts
Why GQG, Imugene, Mirvac, and Temple & Webster Shares Are Pushing Higher
Imugene Therapy Achieves Two Complete Responses in Patients With Blood Cancer, Shares Rise Past 8%
Which ASX 200 Healthcare Share Will Pay the Best Dividend Yield in 2025?
Imugene Receives A$11.7 Million R&D Tax Refund
Imugene Receives A$11.7 Million R&D Tax Refund | ASX:IMU, OTC:IUGNF